论文部分内容阅读
目的探讨凯力康治疗急性脑梗死的临床疗效与对血液流变学指标的影响。方法选取我院神经内科2011年1月～2012年8月收治的急性脑梗死住院患者70例,随机分为两组分别以凯力康与依达拉奉治疗。结果观察组治疗后总有效率为94.3%,对照组治疗后的总有效率为82.9%,观察组患者痊愈率、总有效率均显著高于对照组(P<0.05)。两组患者治疗后全血黏度、血浆粘度、血细胞压积、纤维蛋白原含量均比治疗前明显改善(P<0.05),观察组患者全血黏度、血浆粘度、纤维蛋白原含量改善情况与对照组相比明显较好(P<0.05),两组血细胞压积改善情况无显著差异(P>0.05)。结论凯力康治疗急性脑梗死具有疗效显著的特点,能够有效改善血液流变情况,具有较高的临床价值。
Objective To investigate the clinical efficacy of Keli Kang in the treatment of acute cerebral infarction and its effect on hemorheology indexes. Methods Seventy patients with acute cerebral infarction hospitalized from January 2011 to August 2012 in our department of neurology were randomly divided into two groups, treated with Keli Kang and edaravone. Results The total effective rate was 94.3% in the observation group and 82.9% in the control group. The cure rate and total effective rate in the observation group were significantly higher than those in the control group (P <0.05). After treatment, the whole blood viscosity, plasma viscosity, hematocrit and fibrinogen were significantly improved in both groups (P <0.05), and the improvement of whole blood viscosity, plasma viscosity and fibrinogen in the observation group were compared with those in the control group (P <0.05). There was no significant difference between the two groups in improvement of hematocrit (P> 0.05). Conclusion Keli Kang treatment of acute cerebral infarction with significant efficacy characteristics, can effectively improve the situation of blood rheology, has a high clinical value.